A phase IIa proof of concept study of a novel rho kinase (ROCK) inhibitor, AMA0076 (Amakem NV), is now
underway in patients with glaucoma and ocular hypertension.
Author: ModernMedecine
Valeant acquires AMD treatment
QLT Inc. announces that it has completed sale of Visudyne (verteporfin for injection) to Valeant
Pharmaceuticals International, Inc.
Prompt laser adds naught to ranibizumab in diabetic macular edema
NEW YORK (Reuters Health) – In patients with diabetic macular edema, laser treatment at the start of
intravitreal ranibizumab therapy shows no benefit, according to a new paper.
Facial nerve injury common after temporal artery biopsy
NEW YORK (Reuters Health) – Temporal artery biopsy (TAB) for suspected giant cell arteritis led to
brow ptosis in almost one in six patients in a recent analysis, although most recovered fully.
Phacoemulsification a good option in some with glaucoma
NEW YORK (Reuters Health) – In patients with medically uncontrolled chronic angle-closure glaucoma
without cataract, both phacoemulsification and trabeculectomy are effective but the former can have advantages,
according to Chinese researchers.
Glaucoma no bar to radiotherapy efficacy in iris melanoma
NEW YORK (Reuters Health) – Plaque radiotherapy is an effective therapy for managing iris melanoma in
certain patients and secondary glaucoma has no effect on outcomes, researchers have found.
Radiotherapy may help in Graves’ orbitopathy
NEW YORK (Reuters Health) – Orbital radiotherapy appears to be a safe second-line treatment in
moderate-to-severe Graves’ orbitopathy, but may be less effective than high-dose glucocorticoids, according to a
review by Italians researchers.
CLAO ERF, SSF to sponsor award for dry eye study
A scientific research grant to cover studies related to dry eye and ocular surface disease will be
awarded by CLAO ERF in association with the SSF.
Eye movement affects glaucomatous vision
Certain eye movement patterns seem to be associated with better face recognition performance in
patients with central glaucomatous visual field loss.
Intracorneal inlay now available in Canada
AcuFocus Inc. has received approval from Health Canada to market and sell the Kamra inlay, an
innovative corneal inlay to treat presbyopia, within Canada.
Besifloxacin ophthalmic suspension gains additional indications
The U.S. Food and Drug Administration has granted additional labeling indications for besifloxacin
ophthalmic suspension 0.6% eye drops (Besivance, Bausch + Lomb).
Eylea (aflibercept) for AMD gets EU agency backing
LONDON (Reuters) – EU drugs regulators have recommended Regeneron’s and Bayer’s eye drug Eylea
(aflibercept) for approval in a move likely to see the new medicine eat away further at rival Roche’s market
share.
Regeneron eye drug Eylea wins U.S. approval for new use
Full Story →
Early ocular surface-related complications common after CXL
A study provides new insight on the risk of early ocular surface-related complications among patients
undergoing CXL for keratoconus. » More
Aberrometer receives CE Mark
The iDesign aberrometer (Abbott) provides an advanced, high-definition measurement device for
wavefront-guided LASIK procedures.
Alcon adds to AcrySof family of presbyopia-correcting IOLs
The AcrySof IQ ReSTOR +2.5-D IOL offers sharp distance vision with an additional range of vision
beyond a standard monofocal lens.
Longstanding celiac disease a risk factor for diabetic retinopathy
Full Story →
No increased AMD risk after cataract surgery
NEW YORK (Reuters Health) – There does not appear to be an association between cataract surgery and
progression of age-related macular degeneration (AMD), Australian researchers report.
Editor’s Blog: Can ophthalmology find technological ‘global harmony’?
In today’s blog from ESCRS, Mark Dlugoss, Ophthalmology Times editor-in-chief, discusses ophthalmic
technologies and FDA-related availability issues.
Editor’s Blog: Can ophthalmology find technological ‘global harmony’?
In today’s blog from ESCRS, Mark Dlugoss, Ophthalmology Times editor-in-chief, discusses ophthalmic
technologies and FDA-related availability issues.